blog
Navigating IAS 38: Tips for Capitalising Intangible Assets in Life Sciences
Introduction IAS 38 is a key International Financial Reporting Standard that governs the accounting for intangible assets. It outlines essential principles for recognising, measuring, and disclosing these assets, which can significantly impact financial statements. In...
Understanding IFRS 15: Revenue Recognition for Licensing Deals in Life Sciences
Introduction IFRS 15 is a crucial standard for revenue recognition, particularly in the life sciences sector. This framework provides guidelines for identifying and recognising revenue from contracts with customers, ensuring consistency across industries. Licensing...
Understanding Financial Statements: The Life Sciences Essentials
Financial statements might seem like a maze of numbers, but in life sciences, they tell the story of innovation, progress, and potential. For professionals in biotech and pharmaceutical companies, understanding these fundamental documents is crucial for making...
Financial Statement Red Flags in Life Sciences Companies
Quam, scelerisque ut, mollis sed, nonummy id, metus. Nullam accumsan lorem in dui. Cras ultricies mi eu turpis hendrerit fringilla.
Cash Flow Statements: The Life Sciences Survival Guide
In life sciences, cash is more than king – it is oxygen. Your company might have promising Phase II results and valuable intellectual property, but without careful cash flow management, even the most promising molecule won’t make it to market.
Income Statement Secrets: Beyond Profit and Loss in Biotech
Whilst traditional companies measure success through steady profits, life sciences companies dance to a different tune. Your income statement might show losses for years – and that could be perfectly fine. In fact, it might even signal promising progress in your R&D pipeline.
The Balance Sheet: Your Life Sciences Company’s DNA
If financial statements tell your company’s story, think of the balance sheet as your company’s DNA. For life sciences companies, this crucial document reveals far more than just assets and liabilities – it’s a snapshot of your innovation potential.
Why Life Sciences Companies Need Different Financial Reporting
Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. Donec pede justo, fringilla vel, aliquet nec, vulputate eget, arcu. In enim justo, rhoncus ut.
